# An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07359066/  
OnCo record `nct07359066` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SRP1020 in advanced solid tumours, run by Shanghai SciBrunch Therapeutics Co., Ltd., now recruiting.

## Summary

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07359066 by Shanghai SciBrunch Therapeutics Co., Ltd., with 210 participants planned, started 2026-01-08 and due to reach its primary completion in 2028-02. Interventions recorded: SRP1020.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07359066
- Phase: 1/2
- Setting: An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
- Sponsor: Shanghai SciBrunch Therapeutics Co., Ltd.
- Enrolled: 210

## Sources

- ClinicalTrials.gov NCT07359066: https://clinicaltrials.gov/study/NCT07359066

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07359066.json